As previously reported, Wolfe Research analyst Doug Schenkel initiated coverage of Tempus AI (TEM) with an Outperform rating and $60 price target Tempus AI, a diagnostic company that has built a broad and growing menu of diagnostic tests to address clinical needs and amass genetic and phenotypic data, has been “best-in-class in this category as measured by monetization,” the analyst tells investors. The firm expects Tempus to generate a 30% revenue compound annual growth rate through FY28 as it expects more market penetration, more tests/patient, more menu, and more database monetization.

Pick the best stocks and maximize your portfolio:

• Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!

• Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on TEM:

• Tempus AI initiated with an Outperform at Wolfe Research

• Cathie Wood’s Ark Invest Trims Stake in Tesla

• Cathie Wood’s ARK Investment bought 424.5K shares of Tempus AI today

• Cathie Wood’s ARK Investment bought 84K shares of Tempus AI today

• Largest borrow rate increases among liquid names